Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
Versluis, J.M., Menzies, A.M., Sikorska, K., Rozeman, E.A., Saw, R.P.M., van Houdt, W.J., Eriksson, H., Klop, W.M.C., Ch’ng, S., van Thienen, J.V., Mallo, H., Gonzalez, M., Torres Acosta, A., Grijpink-Ongering, L.G., van der Wal, A., Bruining, A., van de Wiel, B.A., Scolyer, R.A., Haanen, J.B.A.G., Schumacher, T.N., van Akkooi, A.C.J., Long, G.V., Blank, C.U.
Published in Annals of oncology (01.04.2023)
Published in Annals of oncology (01.04.2023)
Get full text
Journal Article
Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients
Groenland, Stefanie L., Janssen, J. M., Nijenhuis, C. M., de Vries, N., Rosing, H., Wilgenhof, S., van Thienen, J. V., Haanen, J. B. A. G., Blank, C. U., Beijnen, J. H., Huitema, A. D. R., Steeghs, N.
Published in Cancer chemotherapy and pharmacology (01.06.2023)
Published in Cancer chemotherapy and pharmacology (01.06.2023)
Get full text
Journal Article
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma
Rawson, R.V., Adhikari, C., Bierman, C., Lo, S.N., Shklovskaya, E., Rozeman, E.A., Menzies, A.M., van Akkooi, A.C.J., Shannon, K.F., Gonzalez, M., Guminski, A.D., Tetzlaff, M.T., Stretch, J.R., Eriksson, H., van Thienen, J.V., Wouters, M.W., Haanen, J.B.A.G., Klop, W.M.C., Zuur, C.L., van Houdt, W.J., Nieweg, O.E., Ch'ng, S., Rizos, H., Saw, R.P.M., Spillane, A.J., Wilmott, J.S., Blank, C.U., Long, G.V., van de Wiel, B.A., Scolyer, R.A.
Published in Annals of oncology (01.06.2021)
Published in Annals of oncology (01.06.2021)
Get full text
Journal Article
Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients
Nijenhuis, C M, Huitema, A D R, Blank, C, Haanen, J B A G, van Thienen, J V, Rosing, H, Schellens, J H M, Beijnen, J H
Published in Journal of clinical pharmacology (01.01.2017)
Published in Journal of clinical pharmacology (01.01.2017)
Get more information
Journal Article
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Jansen, Y.J.L., Rozeman, E.A., Mason, R., Goldinger, S.M., Geukes Foppen, M.H., Hoejberg, L., Schmidt, H., van Thienen, J.V., Haanen, J.B.A.G., Tiainen, L., Svane, I.M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A.M., Long, G.V., Atkinson, V., Blank, C.U., Neyns, B.
Published in Annals of oncology (01.07.2019)
Published in Annals of oncology (01.07.2019)
Get full text
Journal Article
Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma
Geukes Foppen, M.H., Brandsma, D., Blank, C.U., van Thienen, J.V., Haanen, J.B., Boogerd, W.
Published in Annals of oncology (01.06.2016)
Published in Annals of oncology (01.06.2016)
Get full text
Journal Article
Seasonal variation of anti‐PD‐1 outcome in melanoma—Results from a Dutch patient cohort
Borgers, J. S. W., Burgers, F. H., Schina, A., Van Not, O. J., Eertwegh, A. J. M., Blank, C. U., Aarts, M. J. B., Berkmortel, F. W. P. J., Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., Rijn, R. S., Boer, A. M. Stevense‐den, Veldt, A. A. M., Vreugdenhil, G., Boers‐Sonderen, M. J., Wouters, M. W. J. M., Suijkerbuijk, K. P. M., Thienen, J. V., Haanen, J. B. A. G.
Published in Pigment cell and melanoma research (01.01.2024)
Published in Pigment cell and melanoma research (01.01.2024)
Get full text
Journal Article
Is routine skin examination in metastatic melanoma patients treated with immuno‐ or targeted therapy necessary?
Huis in't Veld, E.A., van Seventer, I.C., van Teeseling, L., van Thienen, J.V., Crijns, M.B.
Published in Journal of the European Academy of Dermatology and Venereology (01.04.2020)
Published in Journal of the European Academy of Dermatology and Venereology (01.04.2020)
Get full text
Journal Article
Switch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated melanoma
Reijers, I.L.M., Rozeman, E.A., Mallo, H., Uyterlinde, W., Adriaansz, S., Lijnsvelt, J., Wilgenhof, S., van Thienen, J.V., Haanen, J.B.A.G., Blank, C.U.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned
Borgers, J.S.W., van Schijndel, A.W., van Thienen, J.V., Klobuch, S., Seijkens, T.T.P., Tobin, R.P., van Heerebeek, L., Driessen-Waaijer, A., Rohaan, M.W., Haanen, J.B.A.G.
Published in ESMO open (01.02.2024)
Published in ESMO open (01.02.2024)
Get full text
Journal Article
Phase II study comparing pembrolizumab (PEM) with intermittent/short‐term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra)
Rozeman, E.A., Sikorska, K., Grijpink-Ongering, L., Heeres, B.C., van de Wiel, B.A., Sari, A., Mallo, H., Adriaansz, S., Uyterlinde, W., Lijnsvelt, J., Pronk, L.M., Haanen, J.B.A.G., de Groot, J.W.B., Wilgenhof, S., Vollenbergh, M.A., van Thienen, J.V., Blank, C.U.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma
Rohaan, M.W., Borch, T.H., van den Berg, J.H., Geukes Foppen, M.H., Donia, M., Met, Ö, Nuijen, B., van Zon, M., Bakker, E.A.M., de Boer, R., Pronk, L.M., Wilgenhof, S., Blank, C.U., van Thienen, J.V., van Akkooi, A.C.J., Svane, I.-M., Haanen, J.B.A.G.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial
Rohaan, M.W., Gomez-Eerland, R., van den Berg, J.H., Geukes Foppen, M.H., van Zon, M., Raud, B., Jedema, I., Scheij, S., de Boer, R., Bakker, N.A.M., van den Broek, D., Pronk, L.M., Grijpink-Ongering, L.G., Sari, A., Kessels, R., van den Haak, M., Mallo, H.A., Karger, M., van de Wiel, B.A., Zuur, C.L., Duinkerken, C.W., Lalezari, F., van Thienen, J.V., Wilgenhof, S., Blank, C.U., Beijnen, J.H., Nuijen, B., Schumacher, T.N., Haanen, J.B.A.G.
Published in Immuno-oncology technology (01.09.2022)
Published in Immuno-oncology technology (01.09.2022)
Get full text
Journal Article
1356PIncrease in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma
Rozeman, E A, Moritz, R, Wilgenhof, S, van Thienen, J V, Haanen, J B A G, van den Heuvel, M, Blank, C U, Van Rossum, H
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1259PSwitch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated melanoma
Reijers, I L M, Rozeman, E A, Mallo, H, Uyterlinde, W, Adriaansz, S, Lijnsvelt, J, Wilgenhof, S, van Thienen, J V, Haanen, J B A G, Blank, C U
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
1313PD3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)
Blank, C U, Versluis, J M, Reijers, I L M, Sikorska, K, van Houdt, W J, van Thienen, J V, Adriaansz, S, Mallo, H A, van Tinteren, H, van de Wiel, B A, Grijpink-Ongering, L G, Bruining, A, Haanen, J B A G, van Akkooi, A C J, Schumacher, T N, Rozeman, E A
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
1184PDResults of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma
Rohaan, M W, Gomez-Eerland, R, Foppen, M H Geukes, van Zon, M, de Boer, R, Bakker, N A M, Pronk, L M, Sari, A, Mallo, H A, van de Wiel, B A, Lalezari, F, Beijnen, J H, Nuijen, B, van Tinteren, H, van Thienen, J V, Blank, C U, Wilgenhof, S, Schumacher, T N, van den Berg, J H, Haanen, J B A G
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article